Global Ophthalmic AAV Gene Therapy Market Analysis and Forecast 2025-2031

Summary

According to APO Research, The global Ophthalmic AAV Gene Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Ophthalmic AAV Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Ophthalmic AAV Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Ophthalmic AAV Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Ophthalmic AAV Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Ophthalmic AAV Gene Therapy include GenSight Biologics (Pipeline) and Spark/Roche (Luxturna) etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Ophthalmic AAV Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ophthalmic AAV Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Ophthalmic AAV Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ophthalmic AAV Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Ophthalmic AAV Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Ophthalmic AAV Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.

Ophthalmic AAV Gene Therapy Segment by Company

GenSight Biologics (Pipeline)
Spark/Roche (Luxturna)

Ophthalmic AAV Gene Therapy Segment by Type

Subretinal Injection
Intravitreous Injection

Ophthalmic AAV Gene Therapy Segment by Application

Retinopathy
Optic Atrophy

Ophthalmic AAV Gene Therapy Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmic AAV Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ophthalmic AAV Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmic AAV Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Ophthalmic AAV Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Ophthalmic AAV Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ophthalmic AAV Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Ophthalmic AAV Gene Therapy Market by Type
1.2.1 Global Ophthalmic AAV Gene Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Subretinal Injection
1.2.3 Intravitreous Injection
1.3 Ophthalmic AAV Gene Therapy Market by Application
1.3.1 Global Ophthalmic AAV Gene Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Retinopathy
1.3.3 Optic Atrophy
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Ophthalmic AAV Gene Therapy Market Dynamics
2.1 Ophthalmic AAV Gene Therapy Industry Trends
2.2 Ophthalmic AAV Gene Therapy Industry Drivers
2.3 Ophthalmic AAV Gene Therapy Industry Opportunities and Challenges
2.4 Ophthalmic AAV Gene Therapy Industry Restraints
3 Global Growth Perspective
3.1 Global Ophthalmic AAV Gene Therapy Market Perspective (2020-2031)
3.2 Global Ophthalmic AAV Gene Therapy Growth Trends by Region
3.2.1 Global Ophthalmic AAV Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Ophthalmic AAV Gene Therapy Market Size by Region (2020-2025)
3.2.3 Global Ophthalmic AAV Gene Therapy Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Ophthalmic AAV Gene Therapy Revenue by Players
4.1.1 Global Ophthalmic AAV Gene Therapy Revenue by Players (2020-2025)
4.1.2 Global Ophthalmic AAV Gene Therapy Revenue Market Share by Players (2020-2025)
4.1.3 Global Ophthalmic AAV Gene Therapy Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Ophthalmic AAV Gene Therapy Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Ophthalmic AAV Gene Therapy Key Players Headquarters & Area Served
4.4 Global Ophthalmic AAV Gene Therapy Players, Product Type & Application
4.5 Global Ophthalmic AAV Gene Therapy Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Ophthalmic AAV Gene Therapy Market CR5 and HHI
4.6.3 2024 Ophthalmic AAV Gene Therapy Tier 1, Tier 2, and Tier 3
5 Ophthalmic AAV Gene Therapy Market Size by Type
5.1 Global Ophthalmic AAV Gene Therapy Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Ophthalmic AAV Gene Therapy Revenue by Type (2020-2031)
5.3 Global Ophthalmic AAV Gene Therapy Revenue Market Share by Type (2020-2031)
6 Ophthalmic AAV Gene Therapy Market Size by Application
6.1 Global Ophthalmic AAV Gene Therapy Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Ophthalmic AAV Gene Therapy Revenue by Application (2020-2031)
6.3 Global Ophthalmic AAV Gene Therapy Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 GenSight Biologics (Pipeline)
7.1.1 GenSight Biologics (Pipeline) Comapny Information
7.1.2 GenSight Biologics (Pipeline) Business Overview
7.1.3 GenSight Biologics (Pipeline) Ophthalmic AAV Gene Therapy Revenue and Gross Margin (2020-2025)
7.1.4 GenSight Biologics (Pipeline) Ophthalmic AAV Gene Therapy Product Portfolio
7.1.5 GenSight Biologics (Pipeline) Recent Developments
7.2 Spark/Roche (Luxturna)
7.2.1 Spark/Roche (Luxturna) Comapny Information
7.2.2 Spark/Roche (Luxturna) Business Overview
7.2.3 Spark/Roche (Luxturna) Ophthalmic AAV Gene Therapy Revenue and Gross Margin (2020-2025)
7.2.4 Spark/Roche (Luxturna) Ophthalmic AAV Gene Therapy Product Portfolio
7.2.5 Spark/Roche (Luxturna) Recent Developments
8 North America
8.1 North America Ophthalmic AAV Gene Therapy Revenue (2020-2031)
8.2 North America Ophthalmic AAV Gene Therapy Revenue by Type (2020-2031)
8.2.1 North America Ophthalmic AAV Gene Therapy Revenue by Type (2020-2025)
8.2.2 North America Ophthalmic AAV Gene Therapy Revenue by Type (2026-2031)
8.3 North America Ophthalmic AAV Gene Therapy Revenue Share by Type (2020-2031)
8.4 North America Ophthalmic AAV Gene Therapy Revenue by Application (2020-2031)
8.4.1 North America Ophthalmic AAV Gene Therapy Revenue by Application (2020-2025)
8.4.2 North America Ophthalmic AAV Gene Therapy Revenue by Application (2026-2031)
8.5 North America Ophthalmic AAV Gene Therapy Revenue Share by Application (2020-2031)
8.6 North America Ophthalmic AAV Gene Therapy Revenue by Country
8.6.1 North America Ophthalmic AAV Gene Therapy Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Ophthalmic AAV Gene Therapy Revenue by Country (2020-2025)
8.6.3 North America Ophthalmic AAV Gene Therapy Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Ophthalmic AAV Gene Therapy Revenue (2020-2031)
9.2 Europe Ophthalmic AAV Gene Therapy Revenue by Type (2020-2031)
9.2.1 Europe Ophthalmic AAV Gene Therapy Revenue by Type (2020-2025)
9.2.2 Europe Ophthalmic AAV Gene Therapy Revenue by Type (2026-2031)
9.3 Europe Ophthalmic AAV Gene Therapy Revenue Share by Type (2020-2031)
9.4 Europe Ophthalmic AAV Gene Therapy Revenue by Application (2020-2031)
9.4.1 Europe Ophthalmic AAV Gene Therapy Revenue by Application (2020-2025)
9.4.2 Europe Ophthalmic AAV Gene Therapy Revenue by Application (2026-2031)
9.5 Europe Ophthalmic AAV Gene Therapy Revenue Share by Application (2020-2031)
9.6 Europe Ophthalmic AAV Gene Therapy Revenue by Country
9.6.1 Europe Ophthalmic AAV Gene Therapy Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Ophthalmic AAV Gene Therapy Revenue by Country (2020-2025)
9.6.3 Europe Ophthalmic AAV Gene Therapy Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Ophthalmic AAV Gene Therapy Revenue (2020-2031)
10.2 China Ophthalmic AAV Gene Therapy Revenue by Type (2020-2031)
10.2.1 China Ophthalmic AAV Gene Therapy Revenue by Type (2020-2025)
10.2.2 China Ophthalmic AAV Gene Therapy Revenue by Type (2026-2031)
10.3 China Ophthalmic AAV Gene Therapy Revenue Share by Type (2020-2031)
10.4 China Ophthalmic AAV Gene Therapy Revenue by Application (2020-2031)
10.4.1 China Ophthalmic AAV Gene Therapy Revenue by Application (2020-2025)
10.4.2 China Ophthalmic AAV Gene Therapy Revenue by Application (2026-2031)
10.5 China Ophthalmic AAV Gene Therapy Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Ophthalmic AAV Gene Therapy Revenue (2020-2031)
11.2 Asia Ophthalmic AAV Gene Therapy Revenue by Type (2020-2031)
11.2.1 Asia Ophthalmic AAV Gene Therapy Revenue by Type (2020-2025)
11.2.2 Asia Ophthalmic AAV Gene Therapy Revenue by Type (2026-2031)
11.3 Asia Ophthalmic AAV Gene Therapy Revenue Share by Type (2020-2031)
11.4 Asia Ophthalmic AAV Gene Therapy Revenue by Application (2020-2031)
11.4.1 Asia Ophthalmic AAV Gene Therapy Revenue by Application (2020-2025)
11.4.2 Asia Ophthalmic AAV Gene Therapy Revenue by Application (2026-2031)
11.5 Asia Ophthalmic AAV Gene Therapy Revenue Share by Application (2020-2031)
11.6 Asia Ophthalmic AAV Gene Therapy Revenue by Country
11.6.1 Asia Ophthalmic AAV Gene Therapy Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Ophthalmic AAV Gene Therapy Revenue by Country (2020-2025)
11.6.3 Asia Ophthalmic AAV Gene Therapy Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Ophthalmic AAV Gene Therapy Revenue (2020-2031)
12.2 SAMEA Ophthalmic AAV Gene Therapy Revenue by Type (2020-2031)
12.2.1 SAMEA Ophthalmic AAV Gene Therapy Revenue by Type (2020-2025)
12.2.2 SAMEA Ophthalmic AAV Gene Therapy Revenue by Type (2026-2031)
12.3 SAMEA Ophthalmic AAV Gene Therapy Revenue Share by Type (2020-2031)
12.4 SAMEA Ophthalmic AAV Gene Therapy Revenue by Application (2020-2031)
12.4.1 SAMEA Ophthalmic AAV Gene Therapy Revenue by Application (2020-2025)
12.4.2 SAMEA Ophthalmic AAV Gene Therapy Revenue by Application (2026-2031)
12.5 SAMEA Ophthalmic AAV Gene Therapy Revenue Share by Application (2020-2031)
12.6 SAMEA Ophthalmic AAV Gene Therapy Revenue by Country
12.6.1 SAMEA Ophthalmic AAV Gene Therapy Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Ophthalmic AAV Gene Therapy Revenue by Country (2020-2025)
12.6.3 SAMEA Ophthalmic AAV Gene Therapy Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings